General Biotechnology

The next blockbuster drug may not be a new molecule. It may be an old onerepackaged, recombined and protected by a smarter patent strategy.
That is the uncomfortable reality facing pharmaceutical companies, generic manufacturers and investors navigatin…

Two Expired Patents Can Still Create One Valuable New Patent
A drug can lose the patent protection on its ingredientsand still have another patentable life.
That is the overlooked opportunity in fixed-dose combinations, or FDCs: putting two established…

The FDA Orange Book isnt broken. Its just no longer enough.
For decades, pharmaceutical companies treated the FDAs Orange Book as the starting pointand often the endpointfor understanding drug patent risk.
That made sense when the central question was …

The most expensive mistake in a generic-drug launch may be confusing a five-year clock with a five-year monopoly.
For innovative drugmakers, the phrase five years of NCE exclusivity sounds straightforward. It is not.
New Chemical Entity exclusivity is …

The most expensive mistake in pharma IP strategy may be confusing exclusivity with patent protection.
A drug can have years of regulatory exclusivity leftand still face a patent challenge.
Or it can have a long patent portfoliobut no meaningful regulat…

The Unique Mechanism of Ozempic for Weight Loss: A Comprehensive Guide What is Ozempic? Ozempic, also known as semaglutide,… https://www.Drugchatter.com/chat/37116/what-unique-mechanism-does-ozempic-use-for-weight-loss/

The Unique Mechanism of Ozempic for Weight Loss: A Comprehensive Guide What is Ozempic? Ozempic, also known as semaglutide,… https://www.Drugchatter.com/chat/37116/what-unique-mechanism-does-ozempic-use-for-weight-loss/

The Unique Mechanism of Ozempic for Weight Loss: A Comprehensive Guide What is Ozempic? Ozempic, also known as semaglutide,… https://www.Drugchatter.com/chat/37116/what-unique-mechanism-does-ozempic-use-for-weight-loss/

In generic pharmaceuticals, the biggest mistake may not be launching too early. It may be launching too late.
For years, generic drug strategy was treated as a manufacturing problem: produce a lower-cost version of a branded medicine, secure regulatory…

Your 2-Year Patent Cliff Window May Already Be a 5-Year Problem
A blockbuster drug rarely loses exclusivity on the day its patent expires.
By then, the economics may already be deteriorating.
Generic and biosimilar competitors may be preparing launches…